ArticleFrontiers in pharmacology2024

Comparative analysis of adverse event risks in breast cancer patients receiving pembrolizumab combined with paclitaxel

Yilun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.